GlobeNewswire
-
European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
16/11/2026 -
NewGen Provides Business Update
16/11/2026 -
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
16/11/2026 -
Former Cross Country Healthcare CEO Bill Grubbs Takes Expanded Role as LUKE Executive Chairman
16/11/2026 -
Dr. Robert Langer, Co-Founder of Moderna, Joins PolarityBio’s Board of Directors
16/11/2026 -
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
16/11/2026 -
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
16/11/2026 -
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
16/11/2026 -
Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
16/11/2026 -
Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
16/11/2026 -
Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
16/11/2026 -
BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026
16/11/2026 -
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
16/11/2026 -
VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting
16/11/2026 -
XORTX Completes Manufacturing of Clinical Drug Supply
16/11/2026 -
HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
16/11/2026 -
Novo Nordisk A/S - share repurchase programme
16/11/2026 -
SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™
16/11/2026 -
Nuo Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
16/11/2026
Pages